Mexidol and cognitive testing in 90 older adults with chronic cerebral ischemia
Comparison in people · 2026
- What was studied
- 90 adults, mean age 81 ± 3, with chronic cerebral ischemia and cognitive impairment. Standard care plus Mexidol: 43. Standard care alone: 47.
- Main finding
- At three months, median MMSE was 27 vs 26 points. Schulte test time fell by 8 vs 2 seconds with add-on Mexidol and standard care alone, respectively.
Month 3 · p<0.001
Reported findings and study design
Prospective open comparison with MMSE, Stroop and Schulte testing at baseline and at three months.
Population or model 90 adults, mean age 81 ± 3, with chronic cerebral ischemia and cognitive impairment. Standard care plus Mexidol: 43. Standard care alone: 47.
Dose, route and schedule
Sequential intravenous and oral Mexidol for 74 days, with assessment at three months. The abstract does not specify dose amounts or days on each route.
Protocol source ↗ · Original publisher abstract, group sizes, administration routes and reported cognitive endpoints.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Median MMSE | 27 vs 26 points | Month 3 · p<0.001 |
| Schulte test time | −8.0 vs −2.0 seconds | Reported between-group difference −6.0 seconds (95% CI −9.2 to −2.8) |
| Stroop words named | +7 vs +2 words | Change intervals 5 to 8 vs 0 to 3 (95% CI) |
| Mental stability measure | No significant between-group difference | p>0.05 |
Source for these results ↗ · Reviewed 2026-11-15
Study limitations and source details
Study limitations
- Open prospective comparison. The abstract does not establish randomized allocation, dose amounts, or the clinical importance of the cognitive score differences. This population had chronic ischemia.
Source details
Original publisher abstract, group sizes, administration routes and reported cognitive endpoints.
Sources checked
Citation
Published
O. A. Osipova, E. V. Gosteva, U. S. Moskvitina. Mexidol and cognitive testing in 90 older adults with chronic cerebral ischemia Korsakov Journal of Neurology and Psychiatry. 2026;126(9):84–90.
Study source ↗ · DOI 10.17116/jnevro202612609184 · Bibliography entry · Link to this summary